On Nov. 19, 2015, AquaBounty Technologies announced the U.S. Food and Drug Administration (FDA) had approved the Company’s New Animal Drug Application for the production, sale, and consumption of its AquAdvantage Salmon, an Atlantic salmon that has been genetically enhanced to reach market size in less time than conventional farmed Atlantic salmon. The transgenic fast-growing salmon were created in 1989.

Through greater efficiency and localized production, AquaBounty’s AquAdvantage Salmon increases productivity while reducing costs and the environmental impacts associated with current salmon farming operations. Land-based aquaculture systems can provide a continuous supply of fresh, safe, traceable, and sustainable AquAdvantage Salmon to communities across the U.S. and do it with a reduced carbon footprint. Importantly, it offered an alternative approach to fish farming that does not exploit the oceans.